By Fineline Cube Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China’s National Medical Products Administration (NMPA) for ACC085, its Category 1 novel chemical entity, as a pre-exposure prophylaxis (PrEP) option for adults and adolescents (≥35 kg) at risk of HIV-1 infection.
ACC085 is a first-in-class HIV-1 capsid function inhibitor that disrupts multiple stages of the viral life cycle by binding to the interface between capsid protein subunits—a mechanism distinct from current antiretrovirals. The molecule blocks capsid-mediated nuclear import of proviral DNA, viral assembly and release, and proper capsid core formation, offering a high barrier to resistance.
Development & Regulatory Milestone
| Parameter | Detail |
|---|---|
| Drug Name | ACC085 |
| Classification | NMPA Category 1 (innovative new drug) |
| Mechanism | HIV-1 capsid function inhibitor (multi-step disruption) |
| Indication | Pre-exposure prophylaxis (PrEP) for HIV-1 |
| Target Population | Adults and adolescents ≥35 kg at risk of HIV-1 exposure |
| Regulatory Status | NMPA IND approved for Phase I/II clinical study |
| Origin | Fully indigenous R&D by Aidea Pharma |
Scientific Differentiation
- Multi-Stage Inhibition: Unlike nucleoside analogs or integrase inhibitors, ACC085 targets the structural capsid protein, interfering with early (nuclear entry) and late (assembly/release) viral processes simultaneously.
- Broad-Spectrum Activity: Preclinical data show potent efficacy against diverse HIV-1 strains, including clinical isolates and drug-resistant variants (e.g., NNRTI-, PI-, and INSTI-resistant).
- Long-Acting Potential: Favorable pharmacokinetic profile supports development of extended-release formulations (e.g., monthly oral or injectable), addressing adherence challenges in current daily PrEP regimens.
- In Vivo Efficacy: Demonstrated strong preventive and protective effects in non-human primate and humanized mouse models of HIV-1 infection.
Public Health & Commercial Outlook
- Epidemiological Need: China reports ~100,000 new HIV infections annually, with rising incidence among key populations (MSM, adolescents); only two WHO-recommended PrEP options currently available domestically.
- Market Gap: No long-acting or capsid-targeting PrEP approved in China; ACC085 could become the first homegrown next-generation prevention agent.
- Global Relevance: Capsid inhibitors (e.g., Lenacapavir) are gaining traction worldwide; ACC085 positions Aidea as a potential low-cost, scalable alternative for middle-income markets.
- Next Steps: Aidea plans to initiate a Phase I safety and PK study in Q3 2026, followed by a Phase IIb proof-of-concept PrEP efficacy trial in high-risk cohorts.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market potential. Actual results may vary due to trial outcomes, safety findings, and evolving public health policies.-Fineline Info & Tech